Interleukin-6 (Interleukin 6)

A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS.

Also Known As:

Interleukin 6; IL6; B Cell Stimulatory Factor-2; B-Cell Differentiation Factor; B-Cell Differentiation Factor-2; B-Cell Stimulatory Factor 2; B-Cell Stimulatory Factor-2; BSF-2; Differentiation Factor, B-Cell; Differentiation Factor-2, B-Cell; IFN-beta 2; Interferon beta-2; B Cell Differentiation Factor; B Cell Differentiation Factor 2; B Cell Stimulatory Factor 2; Differentiation Factor 2, B Cell; Differentiation Factor, B Cell; Differentiation-Inducing Protein, Myeloid; Growth Factor, Hybridoma; Growth Factor, Plasmacytoma; Hepatocyte Stimulating Factor; Interferon beta 2; Myeloid Differentiation Inducing Protein; beta-2, Interferon; Hepatocyte-Stimulating Factor; Hybridoma Growth Factor; IL-6; MGI-2; Myeloid Differentiation-Inducing Protein; Plasmacytoma Growth Factor

Networked: 55160 relevant articles (1912 outcomes, 6476 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rose-John, Stefan: 157 articles (04/2022 - 05/2002)
2.	Wang, Wei: 74 articles (10/2022 - 04/2004)
3.	Wang, Jing: 67 articles (11/2022 - 02/2006)
4.	Li, Wei: 62 articles (05/2022 - 04/2002)
5.	Li, Jing: 60 articles (07/2022 - 08/2004)
6.	Liu, Yang: 59 articles (12/2022 - 09/2008)
7.	Li, Yan: 59 articles (09/2022 - 05/2003)
8.	Zhang, Wei: 59 articles (08/2022 - 11/2002)
9.	Wang, Yan: 58 articles (11/2022 - 11/2008)
10.	Kishimoto, Tadamitsu: 58 articles (11/2022 - 01/2002)

Related Diseases

1.	Inflammation (Inflammations) 11/19/1999 - "The bioactivity of interleukin-6 (IL-6) was found to be dramatically reduced in fluids from sites of inflammation. " 10/01/2017 - "Patients with MetS had significantly greater serum IL-6 and TNF-α levels than the controls, supporting the evidence that inflammation plays an important role in the immunopathogenesis of the disease. " 12/04/2023 - "Changes in IL-6 concentrations (ΔIL-6) were significantly greater at 24 h as compared to 48 h post-inflammation (0.652 ± 0.644 vs. -0.146 ± 0.532 pg/μl, P ≤ 0.0001). " 12/01/2023 - "Finally the anti-arthritic effect of the combination of MTX + BA-25 vs MTX alone was investigated using CIA model in DBA/1 mice wherein the treatment with the combination resulted in significant reduction in paw inflammation, IL-6 and IL-1β levels. " 11/07/2019 - "By using IL-6 knockout mice, we further identified that IL-6 deletion provided a significant portion of the protection against inflammation induced by Treg dysfunction. "
2.	Neoplasms (Cancer) 05/01/1994 - "In cancer patients, increased IL-6 serum levels were related to the presence of the tumor since all post-operative patients exhibited a marked decrease. " 10/01/2020 - "Lines cultured with interleukin-6 showed significantly improved correlations with patient tumor (p = 9.5e-4). " 03/21/2017 - "This was associated with reduced tumor cell proliferation and a significant reduction in IL-6, pSTAT3 and TNFα levels. " 01/01/2015 - "A significant reduction in SCF values and a significant increase in OPG and IL-6 values were also observed within cancer cell-positive peritoneal fluid. " 06/01/2010 - "While the in vitro proliferation rates of both transfectants and the parental line were similar, high expression of IL-6 induced a significant reduction in tumor growth in vivo. "
3.	Infections 11/21/2022 - "At the same time, the levels of IL-1β were dramatically improved, while IL-6 lung levels seem to be unaffected by the infection. " 01/01/2023 - "Coinciding with these in vitro results, in vivo murine peritoneal challenge assays showed high increase of IL-6 and improved bacterial clearance in response to infection by the ΔrelAΔspoT double mutant strain. " 10/01/2021 - "A significant reduction in infection, proliferation, and intracellular parasitic load was observed, also an increase in ROS and IL-6. " 03/01/2019 - "A significant reduction (P < 0.01) in IL-6 plasma level in CHB patients compared to healthy controls (22.28 ± 1.93 versus 32.08 ± 2.41), which was negatively correlated (r = -0.216; P < 0.01) with HBV infection. " 01/01/2019 - "Notably, blockade of γIMC-derived IL-6 abrogates Mincle expression, downstream IFN-γ production, and γIMC-mediated protection against severe invasive GAS infection. "
4.	COVID-19 11/24/2020 - "The receiver operating characteristic curve revealed that the combination of IL-6 level, absolute lymphocyte count, and age is superior to a single factor as predictors for severe COVID-19, regardless of whether it is in terms of the area under the curve or the prediction sensitivity and specificity. " 01/01/2020 - "Introduction/objectives: An interleukin-6 inhibition strategy could be effective in selected COVID-19 patients. " 01/01/2022 - "Therefore, when IL-6 cannot be examined, the mNUTRIC score can be considered safe and effective for the prediction of mortality in COVID-19 patients." 10/26/2021 - "A Low-Producing Haplotype of Interleukin-6 Disrupting CTCF Binding Is Protective against Severe COVID-19." 11/01/2021 - "Efficacy of IL-6 antagonists in the treatment of COVID-19 patients: further randomized controlled trials are warranted."
5.	Necrosis 01/01/2018 - "Furthermore, patients with PAD exhibited significantly greater concentrations of the pro-inflammatory markers tumour necrosis factor α in plasma (HC: 0.9 ± 0.4; PAD: 2.0 ± 0.3 pg ml-1 ) and interleukin 6 in both plasma (HC: 2.3 ± 0.4; PAD: 4.3 ± 0.5 pg ml-1 ) and muscle (∼75% greater). " 02/01/2015 - "At the onset of acute Charcot foot, serum concentrations of tumour necrosis factor-α and interleukin-6 were elevated; however, there was a significant reduction in these markers at resolution and these markers may be useful in the assessment of disease activity." 12/01/2019 - "The combination of DOX and KIR may promote therapeutic efficacy, at which the anti-apoptotic effect of the tumour cells was inhibited (by downregulating Bcl-2 and upregulating Bax) and the tumour progression-related inflammatory factors, such as tumour necrosis factor α (TNF-α) and interleukin-6 (IL-6) were downregulated. " 09/01/2023 - "The efficacy of the injury model was gauged by detecting the presence of tumour necrosis factor-α and interleukin-6. " 01/01/2021 - "This study evaluated interleukin-6 (IL-6) and tumour necrosis factor α (TNFα) expression in two subgroups of CF patients classified based on PA. "

Related Drugs and Biologics

1.	Cytokines
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	Interleukin-10 (Interleukin 10)
4.	Interleukin-8 (Interleukin 8)
5.	C-Reactive Protein
6.	Proteins (Proteins, Gene)
7.	tocilizumab (atlizumab)
8.	Interleukins
9.	Messenger RNA (mRNA)
10.	Interleukin-1 (Interleukin 1)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Drug Therapy (Chemotherapy)
4.	Transplantation
5.	Immunotherapy